Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Discovery & Translation

AACR22 tackles the CAR T solid tumor challenge

Dual-targeting CARs, new targets and bispecific adaptors among the top innovations

March 25, 2022 11:32 PM UTC

Solid tumors are the next frontier for CAR T cell therapies, and researchers are using AACR22 to showcase new technologies to address the biggest obstacles to moving the modality beyond blood cancers.

Those hurdles include finding solid tumor-selective targets, addressing the heterogeneity of solid tumors, and overcoming the suppressive effects of the solid tumor microenvironment...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article